An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf) Plus Cobimetinib (Cotellic) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms RadioCoBRIM
- 16 Apr 2019 Planned End Date changed from 31 Aug 2021 to 1 Jul 2022.
- 16 Apr 2019 Planned primary completion date changed from 31 Aug 2019 to 1 Jul 2022.
- 26 Feb 2018 Status changed from not yet recruiting to recruiting.